Should We Start Using the Retrograte Access in Critical Limb Ischemia?

Courtesy of Dr. Carlos Fava.

Peripheral vascular disease in lower limbs is on the rise. Antegrade recanalization is associated with amputation and death, and therefore contraindicated.

Nuevas estrategias en el territorio femoropoplíteo

For a while we have been using the retrograde access when classic revascularization is not possible.

Even though there is evidence in favor of this access, it is just a small series and very diverse groups of patients. In addition, this strategy requires a steep learning curve.

The study included 524 patients with peripheral vascular disease. 70% presented critical limb ischemia; 554 limbs.


Read also: The Real Impact of Peripheral Artery Disease in TAVR.


Mean age was 72, 63% were men, 62.5% were diabetic, 50% had kidney function deterioration and 5.7% were in dialysis.

The presence of total occlusions was 35.6% in femoropopliteal territory, 42.6% in infrapopliteal territory and 21.6% in both, with average length 19.4 cm.

Procedural success was 89%. Puncture related complications were 3.3%.

At 30 days, mortality was 21 patients (4%). They all presented critical limb ischemia, pseudoaneurysm 3.2% and surgery for bleeding or pseudoaneurysm 1.3%.


Read also: ESC 2019 | How Benign Is Moderate Aortic Stenosis?


At one year, freedom from target lesion revascularization and restenosis was 74.6% and 67.5% in those presenting intermittent claudication and 62.2% and 36% in those presenting critical limb ischemia respectively.

At four years, mortality was 24.5% and major amputation was 8.6%. Both events were significantly larger in patients presenting critical limb ischemia, as well as clinically driven target lesion revascularization.

Conclusion

Retrograde tibioperoneal access is safe for complex infrainguinal total occlusions after failed antegrade access. Puncture site complications are rare.

Courtesy of Dr. Carlos Fava.

Original title: Retrograde Tibioperoneal Access for Complex Infrainguinal Occlusions Short- and Long-Term Outcomes of 554 Endovascular Interventions.

Reference: Andrej Schmidt, et al. J Am Coll Cardiol Intv 2019;12:1714–26.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...